By Nigam Arora 215 Buyouts — A New Record of Success for Arora Members Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out. This milestone demonstrates the strength of The Arora Report’s approach. Neuromuscular Diseases
By Nigam Arora & Dr. Natasha Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules
By Nigam Arora & Dr. Natasha Arora To gain an edge, this is what you need to know today. Important Data Ahead Please click here for a chart of Nasdaq 100 ETF (QQQ). Note the following: The chart shows that Nasdaq 100 has pulled back after touching the low band of the resistance zone.
New developments in clinical trials and drug approvals have become commonplace. And buyouts of biotech stocks at high premiums are increasing. Here is how to get your share of the outsized gains that are being generated. Let’s explore the issue with the help of two charts. Please click here for an annotated
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market
This post was just published on ZYX Buy Change Alert. A large number of subscribers are holding General Cable (BGC) stock from $10. Newer subscribers are holding BGC from as high as $21. BGC has received a $30 cash buyout offer from Prysmian Group. The Arora Report had previously identified BGC as a takeover
Not long ago, French pharmaceutical company Advanced Accelerator Applications got a lot of publicity. Now it’s getting bought out. The late Apple AAPL, co-founder Steve Jobs died from pancreatic cancer, specifically from a neuroendocrine tumor, or islet cell carcinoma. Advanced Accelerator Applications AAAP, became famous because of its work on
This post was just published on ZYX Buy Change Alert. Advanced Accelerator Applications (AAAP) stock is long from $40.50. AAAP has received an $82 cash buyout offer from Novartis (NVS). You have doubled your money if you followed us on this trade. This is 130th buyout or M&A of one of our portfolio
This post was just published on ZYX Buy Change Alert. Advanced Accelerator Applications (AAAP) stock is long from $40.50. As of this writing it is trading at $66.65. AAAP’s lutetium, the treatment for the cancer that killed Steve Jobs of Apple (AAPL), has been approved by the European Commission. This good news is
This post was published on ZYX Buy Change Alert. Advanced Accelerator Application (AAAP) stock is long from $40.50. It traded as high as $70 in the pre market before pulling back on rumors that Novartis (NVS) will make a buyout offer. If a buyout occurs it will be 129th buyout of one of our